Status:

COMPLETED

Human Ovarian Follicular Dynamics and Emergency Contraception

Lead Sponsor:

University of Saskatchewan

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Contraception

Eligibility:

FEMALE

18-40 years

Phase:

PHASE4

Brief Summary

The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attribut...

Detailed Description

This study is a single-center, randomized, open-label, double-controlled protocol to study the pattern of ovarian follicular growth and regression in two groups of women. The first group will use Plan...

Eligibility Criteria

Inclusion

  • Female volunteers of childbearing potential;
  • Are first time users of oral contraception (OC) or have discontinued OC at least 1 month prior to study entry;
  • Age between 18 and 40 years old;
  • Normal body mass index (18-38);
  • Has signed informed consent form; and
  • Is in good health as confirmed by medical history, physical examination.

Exclusion

  • A positive pregnancy test will automatically exclude the volunteer from participation in this study.
  • Any contraindication for oral contraception use;
  • Irregular menstrual cycles;
  • Ultrasonographic evidence of ovarian dysfunction, such as polycystic ovary syndrome (PCOS);
  • Pregnancy (suspected or diagnosed) or lactation;
  • History or suspicion of drug or alcohol abuse;
  • Participation in an investigational drug trial within the 30 days prior to selection;
  • Exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
  • history of, or actual, thrombophlebitis or thromboembolic disorders.
  • history of, or actual, cerebrovascular disorders.
  • history of, or actual, myocardial infarction or coronary artery disease.
  • acute liver disease.
  • history of, or actual, benign or malignant liver tumors.
  • history of, or suspected, carcinoma of the breast.
  • known, or suspected, estrogen-dependent neoplasia.
  • undiagnosed abnormal vaginal bleeding.
  • any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual field.

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

End Date :

June 1 2006

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00204451

Start Date

July 1 2005

End Date

June 1 2006

Last Update

November 28 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ob-Gyn Royal University Hospital

Saskatoon, Saskatchewan, Canada, S7N 0W8